Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP1223
- Development stage
- Preclinical
- Lead developer
- BrightPath Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BP1223 is an investigational bispecific antibody developed by BrightPath Biotherapeutics that simultaneously targets CD39 and CD3. CD39 (ectonucleoside triphosphate diphosphohydrolase 1) is an ectoenzyme frequently overexpressed on acute myeloid leukemia (AML) cells and within the tumor microenvironment, where it facilitates the conversion of extracellular ATP into immunosuppressive adenosine. By binding to CD3 on T cells and CD39 on malignant cells, BP1223 acts as a T-cell engager, redirecting T-cell cytotoxicity to induce the lysis of CD39-positive cancer cells. The drug is currently in preclinical development for hematologic malignancies, including AML, multiple myeloma (MM), and chronic myeloid leukemia (CML), with preclinical data presented at the American Society of Hematology (ASH) Annual Meeting in 2024.
- Other names
- CD39xCD3 bispecific antibodyCD-39xCD3 bispecific antibodyCD 39xCD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)
Beyond the preview
Go deeper on BP1223.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP1223.